FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:994-995 April 11, 1996 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Schwartz, R. S.

To the Editor: Robert Schwartz, in his review of Arthur Kornberg's book The Golden Helix: Inside Biotech Ventures (Nov. 9 issue),¹ chastises faculty members for seeking personal profit from connections with industry formed through biotechnology ventures but accepts as normal industrial support that comes to universities for clinical studies of drugs or devices. To me these value judgments are inverted. Surely, the translation of laboratory discoveries into innovative clinical applications fulfills the mission of a university more appropriately than do the routine developments engendered by a multicenter phase 3 study. It seems highly unlikely that the revolution in biotechnology that . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.